ClinicalTrials.gg
Not yet recruitingNCT07436221Updated Feb 27, 2026

A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Asthma

A Phase 2 interventional study of AK139 and AK139 in Asthma, sponsored by Akeso. Not yet recruiting at 2 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Akeso · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 251 studies in Asthma with a site in China — 87 open to participants now, 96 under way, 15 of them phase 3. Asthma · China.

Planned enrollment
105th of 182
160 · median 203
Started
2026
with 19 others
Phase 2
39 of 251
19 open now
Primary completion
2026-12
later than 36 of 95 live
Registered
231st of 251
by date

Among the 251 studies in Asthma with a site in China, this one is the 105th largest by planned enrollment of the 182 interventional ones that give a count, is one of 20 that started in 2026, is one of 39 in phase 2, reaches primary completion later than 36 of the 95 other live ones, and was the 231st registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

87 of the 251 studies in Asthma with a site in China are open now. Recruiting first, the newest first:

82 more — sign in →

All 87 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 251 studies in Asthma with a site in China, or all of them as a file.
02

Study summary

This is a randomized, double-blind phase II clinical study to evaluate the efficacy and safety of AK139 in the treatment of participants with moderate to severe asthma.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosed with asthma at least one year;
  2. Evidence of the reversibility of airflow limitation meets the requirements of the protocol;
  3. Pre-bronchodilator (FEV1) meets the requirements of the protocol at screening and baseline;
  4. Asthma Control Questionnaire 5-question version (ACQ-5) score≥1.5 at screening and baseline;
  5. The participants agree to use highly effective methods from the moment of signing of the ICF to 3 months after the last dose of the product.

Exclusion criteria

Exclusion Criteria:

  1. Concomitant respiratory diseases that, as determined by investigators, may affect the evaluation of therapeutic effects or safety of the product;
  2. A participant who experiences a severe asthma exacerbation at any time from 4 weeks prior to the screening up to and including the baseline;
  3. Allergic to any component of the investigational product or intolerant to basis treatment;
  4. Ongoing use of prohibited treatments. detailed in the protocol have to be adhered to;
  5. Other reasons the investigators believe that the participants are not suitable to enrolled in this study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    AK139 regimen 1

    Drug: AK139

  • Experimental
    AK139 regimen 2

    Drug: AK139

  • Experimental
    AK139 regimen 3

    Drug: AK139

  • Experimental
    Placebo

    Drug: Placebo

Interventions

  • DrugAK139

    AK139 regimen 1- subcutaneous injection.

  • DrugAK139

    AK139 regimen 2- subcutaneous injection.

  • DrugAK139

    AK139 regimen 3- subcutaneous injection.

  • DrugPlacebo

    subcutaneous injection.

06

What researchers measure

Primary outcomes

  1. Absolute change from baseline in pre-bronchodilator FEV1

    Time frame: Up to week 12

  2. Absolute change and percent change from baseline in FENO

    Time frame: Up to week 12

Secondary outcomes

  1. Adverse events (AEs), serious adverse events(SAEs)

    Time frame: Up to week 4

  2. Serum AK139 concentration

    Time frame: Up to week 20

  3. Immunogenicity characteristics of AK139

    Number of participants with detectable anti-drug antibodies (ADA) and neutralizing antibodies (Nab) after treatment.

    Time frame: Up to week 20

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for Dec 2026, 9 months later.

Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's planned 9 months is below that.

Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2026
First posted
Feb 27, 2026
StartEst.
Feb 28, 2026
Primary completionEst.
Dec 27, 2026
CompletionEst.
Feb 26, 2027
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07436221
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Feb 28, 2026 (estimated)
Primary completion
Dec 27, 2026 (estimated)
Completion
Feb 26, 2027 (estimated)
Last update
Feb 27, 2026

Study contacts

Guoqin Wang
Contact
global.trials@akesobio.com
+86 (0760) 8987 399

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AK139

Start the discussion